“Mender” Supplement Firm Hopes To Reopen After Mending Its Violations
This article was originally published in The Tan Sheet
Executive Summary
BioAnue Labs says it temporarily stopped selling its products, which FDA warned are unapproved new drugs due to claims the firm made. BioAnue’s website and others associated with the firm continue to advertise supplements under brands that include a common disease name and terms that refer to treating the condition.
You may also be interested in...
Hi-Tech CEO Could Face Jail For Violating Court Order To Recall Weight Loss Products
A federal judge soon will decide whether Hi-Tech Pharmaceuticals CEO Jared Wheat goes to jail for failing to recall weight loss products marketed with false claims. Wheat has a history of run-ins with FDA, FTC and DEA for marketing supplements adulterated with drugs and making false claims for products.
FDA News In Brief
Dickinson installed as permanent chief counsel; Schwabe’s Umcka homeopathics deemed new drugs for cold/flu claims; inadequate GMPs weigh on Vitagenic; more FDA In Brief.
US FDA Supplement Facility Inspection Numbers Back To Typical Along With GMP Problems Found
Supplement facility GMP inspections by FDA in 2022 along with the frequency of form 483s sent to firms following inspections return to roughly pre-pandemic annual numbers after dipping during 2020 and 2021.